This website is for UK Healthcare Professionals only

BOTOX®: tried and tested for treating chronic migraine5-25*

+9 YEARS of real-world experience demonstrating reduction in headache days5-25 with evidence from 20 studies in eight countries5-25


BOTOX® could have a positive impact on the lives and future outlook of your patients with
chronic migraine4-6


In an international, multicentre, long-term, open-label, single-arm prospective study in patients with chronic migraine:4,26


In a prospective, real-world study of patients with chronic migraine, patients missed work on average 4x fewer days per month after initiating BOTOX® treatment compared with before (n=58)7
Pre-treatment median: 4 (IQR: 3-6)
Post-treatment median: 1 (IQR: 0-4)


Kayte's treatment journey

Kayte was diagnosed with chronic migraine at 24, and experienced issues with certain treatments before finding one that suited her. Learn about her individual experience in this video.

Patient case based on a real-life patient. This is Kayte’s personal story, and this will not be the same experience for all patients with chronic migraine.


*BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).27

CM: chronic migraine; FDA: Food and Drug Administration; GAD-7: 7-item Generalized Anxiety Disorder Assessment; IQR: interquartile range; PHQ-9: Patient Health Questionnaire-9; SD: standard deviation.

 

References

  1. Allergan Ltd. Data on file 014
  2. Allergan. Data on file. INT/0423/2016
  3. Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358-1373
  4. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
  5. Grazzi L, Usai S. Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience. Neurol Sci 2015;36 Suppl 1:33-35
  6. Stark C, Stark R et al. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study. J Headache Pain 2019;20(1):81
  7. Khalil M, Zafar H W et al. Prospective analysis of the use of onabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK. J Headache Pain 2014;15:54
  8. Aicua-Rapun I, Martinez-Velasco E et al. Real-life data in 115 chronic migraine patients treated with onabotulinumtoxin A during more than one year. J Headache Pain 2016;17(1):112
  9. Alina Buture, Ahmed F. OnabotulinumtoxinA (Botox) in chronic migraine with and without medication overuse. Curr Neurobio 2016;7(1):13-15
  10. Aydinlar E I, Dikmen P Y et al. OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study. J Headache Pain 2017;18(1):23
  11. Byun J I, Sim J Y, Kim M. Prolonged effect of onabotulinumtoxinA on chronic migraine in 87 Koreans. J Clin Neurol 2017;13(1):98-100
  12. Cernuda-Morollon E, Ramon C et al. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain 2015;156(5):820-824
  13. Demiryurek B E, Ertem D H et al. Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine. Neurol Sci 2016;37(11):1779-1784
  14. Grazzi L. Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results of a long-term treatment. Neurol Sci 2017;38(Suppl 1):141-143
  15. Guerzoni S, Pellesi L et al. Increased efficacy of regularly repeated cycles with onabotulinumtoxinA in MOH patients beyond the first year of treatment. J Headache Pain 2015;17:48
  16. Kollewe K, Escher C M et al. Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting. J Neural Transm (Vienna) 2016;123(5):533-540
  17. Lee M J, Lee C et al. Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: a clinic-based prospective study. J Neurol Sci 2016;363:51-54
  18. Lia C, Tosi P et al. Onabotulinumtoxin A for prophylaxis in chronic migraine: preliminary data from Headache Regional Centre of Aosta Valley. Neurol Sci 2014;35 Suppl 1:175-176
  19. Negro A, Curto M et al. OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. Springerplus 2015;4:826
  20. Negro A, Curto M et al. A two years open-label prospective study of onabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain 2015;17:1
  21. Pedraza M I, de la Cruz C et al. OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. Springerplus 2015;4:176
  22. Russo M, Manzoni G C et al. The use of onabotulinum toxin A (Botox) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study. Neurol Sci 2016;37(7):1127-1131
  23. Santoro A, Fontana A et al. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting. Neurol Sci 2017;38(10):1779-1789
  24. Vikelis M, Argyriou A A et al. Onabotulinumtoxin-A treatment in Greek patients with chronic migraine. J Headache Pain 2016;17(1):84
  25. Andreou A P, Trimboli M et al. Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal. Eur J Neurol 2018;25(8):1069-e1083
  26. Blumenfeld A M, Tepper S J et al. Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. J Neurol Neurosurg Psychiatry 2019;90(3):353-360
  27. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed April 2022
 

Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

 

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

 

Date of preparation: April 2022. UK-BCM-220064.